ACP3 and prostate carcinoma: The prostate cancer full length antigens investigated in detail have focused onprostate-specific membrane antigen (PSMA), PSA and prostatic acid phosphatase (PAP)expressed through viral vectors, DNA vaccines, and personalized peptide vaccines [10, 11].